Industry BlueBook

Pharma Services: Development

November 2022

The industry's authoritative information resource for valuations, M&A transactions, and Financings


DASHBOARD^{1,2,3,4,5}

| EV MULTIPLES | | | | | | | | | |
|---------------------------------------|------|-----|---------|-----|--------|-----|-------|-----|--|
| | | | REVENUE | | EBITDA | | | | |
| | LTM | %∆ | FTM | %∆ | LTM | %∆ | FTM | %∆ | |
| Development Technology & Info Systems | 8.5x | 12% | 7.6x | 13% | 34.4x | 12% | 22.2x | 12% | |
| Development Clinical Services | 3.2x | 4% | 3.1x | 4% | 15.0x | 3% | 14.1x | 4% | |
| Development Laboratory Services | 4.0x | NM | 3.4x | NM | 21.6x | NM | 15.7x | 2% | |


| M&A DEALS & FINANCINGS | | | | | | | | | |
|---------------------------------------|--------------------------|------|------------|-----|---|-----|-------------|------------|------|
| | DEAL COUNT VOLUME (\$MM) | | | | | | LUME (\$MM) | | |
| | M&A | %∆ | FINANCINGS | %∆ | _ | M&A | %∆ | FINANCINGS | %∆ |
| Development Technology & Info Systems | 2 | 100% | 12 | 20% | | 0 | NM | 145 | NM |
| Development Clinical Services | 1 | 0% | 2 | | | 0 | | 85 | |
| Development Laboratory Services | 0 | NM | 5 | 67% | | 0 | NM | 136 | 100% |

- . Enterprise value (EV) equals equity market value (market capitalization) plus debt, plus preferred stock, minus cash and cash equivalents
- 2. Deals counted once in total if included in multiple segments
- 3. LTM = last twelve months; FTM = forward twelve months
- 4. $\%\Delta$ percent change month over month
- 5. NM Not Meaningful


12 Month Deal Count M&A




12 Month Volume M&A (\$MM)



12 Month Deal Count Financings




12 Month Volume Financings (\$MM)



M&A ACTIVITY

DEALS BY SEGMENT

Drug Development



U.S. DEALS BY STATE



WORLDWIDE DEALS BY COUNTRY



| SELECTE | D TRANSA | CTIONS | | | | |
|----------------|------------------|------------------|-----------------------------------|----------------|---|-------------|
| Announced Date | Segment | Sub-Segment | Target Company | Geography | Selected Buyers | Size (\$mm) |
| 11/17/2022 | Clinical Service | Trial Execution | Egin Research Ltd | United Kingdom | Velocity Clinical Research Inc. | - |
| 11/14/2022 | eClinical | Data Acquisition | Telix Optimal Tracers, LLC | United States | Telix Pharmaceuticals Limited (ASX:TLX) | - |
| 11/2/2022 | eClinical | Operations Tech | CSS Health and Integrity Pharmacy | United States | Clarest Health | _ |


FINANCINGS

DEALS BY SEGMENT

Drug Development

| eClinical | Clinical | Service | | |
|-----------------------|-------------------|---------------------|---------|--------------------------|
| | | Trial Execution | Regulat | cory Services |
| Data Science Tools | Clinical Trial | Clinical Support | Data | a Services |
| | Data | Lab Services | | |
| Operations Technology | Acquisition | Esoteric Laboratory | | Bioanalytical Testing |

U.S. DEALS BY STATE



WORLDWIDE DEALS BY COUNTRY



| SELEC | TED TRANS | SACTIONS | | | | |
|-------------|-------------------------------|--|------------------------------|---------------|--|-------------|
| Closed Date | Segment | Sub-Segment | Target Company | Geography | Selected Investors | Size (\$mm) |
| 11/30/2022 | eClinical Clinical Service | Data Acquisition Trial Execution Data Services | Vial Health Technology, Inc. | United States | General Catalyst Group Management, LLC, BoxGroup Services, LLC, Byers Capital Management LLC | 67.0 |
| 11/28/2022 | Lab Services | Esoteric | Strand Therapeutics Inc. | United States | Five Paces Ventures, LP, Greenspring Associates, Inc., Playground Global, LLC, Potentum Partners, L.P. | 97.0 |
| 11/23/2022 | eClinical | Data Science Tools | RedBrick AI Private Limited | India | Sequoia Capital India Advisors Private Limited, Y Combinator Management LLC | 4.6 |

| Closed Date | Segment | Sub-Segment | Target Company | Geography | Selected Investors | Size (\$mm) |
|-------------|---------------------------|---|----------------------------------|----------------|---|-------------|
| 11/21/2022 | eClinical | Data Science Tools | Capitol AI, Inc. | United States | Designer Fund, LLC, 468 Capital, Sanno Capital GmbH, AirAngels | 10.0 |
| 11/17/2022 | eClinical | Data Science Tools | GeoH, Inc. | United States | Boomerang Ventures, First Leaf Capital, VisionTech | 2.0 |
| 11/17/2022 | eClinical | Data Science Tools | Subtle Medical | China | 3E Bioventures Capital, SFC Capital, Delta Capital, 3E Bioventures Capital, Crista Galli Ventures | 20.0 |
| 11/17/2022 | Lab Services | Esoteric | transOMIC technologies inc. | United States | Imunon, Inc. (NasdaqCM:IMNN) | 0.4 |
| 11/15/2022 | eClinical | Data Acquisition | Aide Health Limited | United Kingdom | Fuel Ventures Limited, Hambro Perks Ltd., Axel Springer Porsche GmbH & Co. KG, 1818 Venture Capital | 1.2 |
| 11/15/2022 | eClinical | Operations Tech Data Science Tools | PayZen Inc. | United States | 7wire Ventures | 20.0 |
| 11/15/2022 | Lab Services | Esoteric | Novigenix SA | Switzerland | Undisclosed | 20.0 |
| 11/14/2022 | eClinical | Data Science Tools | Validic, Inc. | United States | The Ziegler Companies, Inc., Blue Shield Of California Foundation, Greycroft LP, Greycroft LP, Green Park & Golf Ventures LLC, Gore Range Capital LLC | 12.0 |
| 11/14/2022 | Lab Services | Bioanalytical Testing | Beijing Daxiang Biotech Co., Ltd | China | Proxima Ventures, Shaanxi Shantou Capital Management | 14.0 |
| 11/9/2022 | Clinical Service | Clinical Support Regulatory Services | NRG Therapeutics Ltd | United Kingdom | Brandon Capital Partners, Omega Fund Management, LLC, Parkinson's Virtual Biotech | 18.3 |
| 11/9/2022 | eClinical | Data Acquisition | WearOptimo Pty Ltd | Australia | The Australian National University, Aspen Medical Pty Limited | 3.2 |
| 11/8/2022 | eClinical Lab Services | Data Science Tools Esoteric | Sequencing Inc. | United States | Global Founders Capital Management GmbH, Correlation Ventures, L.P., Lerer Hippeau Ventures Management, LLC, Red Sea Ventures, Red Sea Ventures, XRC Labs, Red Antler, LLC, Gaingels, LLC | 5.0 |
| 11/3/2022 | eClinical | Operations Tech | Remedo Clinitech Pvt Ltd | India | Whiteboard Capital Advisors LLP, SucSeed Venture Partners LLP, Titan Capital | - |
| 11/2/2022 | eClinical | Operations Tech | Protera Health, Inc. | United States | Undisclosed | 0.3 |

PUBLIC MARKETS¹

| DEVELOPMEN [®] | DEVELOPMENT TECHNOLOGY & INFO SYSTEMS | | | | | | | | | | |
|-------------------------|---------------------------------------|------------------|----------|--------|--------|--------|--|--|--|--|--|
| Company Nama | Goography | Enterprise Value | xRevenue | | xEBITE |)A | | | | | |
| Company Name | Geography | (\$mm) | LTM EV | FTM EV | LTM EV | FTM EV | | | | | |
| QuintilesIMS | United States | 51,787 | 3.6x | 3.4x | 17.8x | 14.4x | | | | | |
| Veeva Systems | United States | 26,704 | 13.4x | 11.7x | 51.0x | 30.0x | | | | | |
| Mean | | 39,246 | 8.5x | 7.6x | 34.4x | 22.2x | | | | | |
| Median | | 39,246 | 8.5x | 7.6x | 34.4x | 22.2x | | | | | |

| DEVELOPMENT CLINICAL SERVICES | | | | | | |
|---|---------------|------------------|--------|--------|---------|--------|
| Company Name | Geography | Enterprise Value | xReve | enue | xEBITDA | |
| Сопірану Маше | Geography | (\$mm) | LTM EV | FTM EV | LTM EV | FTM EV |
| Charles River Laboratories International, Inc. (NYSE:CRL) | United States | 14,832 | 3.9x | 3.6x | 14.9x | 14.3x |
| CMIC HOLDINGS Co., Ltd. | Japan | 354 | 0.5x | 0.5x | 2.9x | 4.3x |
| ICON PIc. | Ireland | 21,997 | 2.9x | 2.7x | 15.1x | 13.8x |
| Linical Co., Ltd. | Japan | 100 | 1.2x | 1.1x | 9.8x | 7.5x |
| Medpace | United States | 6,777 | 4.9x | 4.2x | 21.6x | 20.9x |
| QuintilesIMS | United States | 51,787 | 3.6x | 3.4x | 17.8x | 14.4x |
| Seiko Epson Corporation | Japan | 4,671 | 0.5x | 0.5x | 4.2x | 4.0x |
| Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) | Japan | 873 | 6.1x | 4.9x | 15.1x | 15.8x |
| Syneos Health, Inc. | United States | 6,492 | 1.2x | 1.3x | 7.9x | 8.5x |
| WuXi AppTec | China | 31,647 | 6.5x | 5.1x | 25.2x | 18.3x |
| Mean | | 13,953 | 3.1x | 2.7x | 13.4x | 12.2x |
| Median | | 6,635 | 3.2x | 3.1x | 15.0x | 14.1x |

| Company Name | Coography | Enterprise Value | xRev | enue | xEBITDA | |
|---|---------------------|------------------|--------|--------|---------|--------|
| Company Name | Geography | (\$mm) | LTM EV | FTM EV | LTM EV | FTM EV |
| Champions Oncology, Inc. | United States | 94 | 1.8x | 1.6x | 22.2x | 22.2x |
| Charles River Laboratories International, Inc. (NYSE:CRL) | United States | 14,832 | 3.9x | 3.6x | 14.9x | 14.3x |
| Eurofins Scientific SE | Luxembourg | 15,961 | 2.3x | 2.3x | 9.1x | 9.5x |
| Evotec SE (XTRA:EVT) | Germany | 2,748 | 3.8x | 3.4x | 46.8x | 15.7x |
| Frontage Holdings Corporation (SEHK:1521) | United States | 604 | 2.8x | 2.1x | 10.1x | 10.1 |
| ICON PIc. | Ireland | 21,997 | 2.9x | 2.7x | 15.1x | 13.8> |
| Joinn Laboratories (China) Co.,Ltd. (SHSE:603127) | China | 3,653 | 13.4x | 9.1x | 39.7x | 36.6> |
| KNOTUS Co.,Ltd | Korea (Republic of) | 292 | 4.7x | NM | 35.7x | NM |
| Medpace | United States | 6,777 | 4.9x | 4.2x | 21.6x | 20.9> |
| Pharmaron Beijing Co., Ltd. (SZSE:300759) | China | 10,544 | 7.8x | 5.9x | 34.6x | 22.2> |
| Selvita S.A. (WSE:SLV) | Poland | 352 | 4.0x | 3.2x | 21.6x | 12.7> |
| Shanghai Medicilon Inc. | China | 2,587 | 11.3x | NM | 40.2x | NM |
| Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) | Japan | 873 | 6.1x | 4.9x | 15.1x | 15.8 |

| Syneos Health, Inc. | United States | 6,492 | 1.2x | 1.3x | 7.9x | 8.5x |
|---------------------|---------------|--------|------|------|-------|-------|
| WuXi AppTec | China | 31,647 | 6.5x | 5.1x | 25.2x | 18.3x |
| Mean | | 7,964 | 5.2x | 3.8x | 24.0x | 17.0x |
| Median | | 3,653 | 4.0x | 3.4x | 21.6x | 15.7x |

RECENT CROSSTREE TRANSACTIONS

Crosstree Capital Partners provides mergers and acquisitions and financing advisory services exclusively to leading Health Sciences companies. Since inception, the firm has been a consistent leader within our focus areas, closing more than 100 successful transactions with companies ranging from private equity-backed consolidators to Fortune 500 publicly-traded companies. In the process, we have represented clients on five continents, and roughly 35% of our transactions have been cross-border.

















Contact Us

Shane Senior, CFA
Head of Pharma Services
813-774-4755
shane.senior@crosstreecapital.co
m www.crosstreecapital.com

Location

Tampa (Headquarters)
5411 Skycenter Dr. Suite 625
Tampa, FL
33607